Tour the DUPIXENT
convention experience
at ATS 2020 Virtual
EXPLORE
TODAY
DUP.20.07.0010

DISCOVER
A PATH

TO ASTHMA
CONTROL

99.9% of insurance
plans require no biomarker
testing for OCS-dependent
asthma patients4

VIEW COVERAGE DATA


Identify the range of
patients appropriate
for DUPIXENT

BUILD A PATIENT

DUPIXENT is a dual inhibitor of IL-4 and IL-13 signaling and is not an immunosuppressant2

EXPLORE THE MOA
The mechanism of dupilumab action in asthma has not been established.
NOW APPROVED
The DUPIXENT 300 mg
Pre-filled Pen will be
available by late August
2020
for appropriate
patients aged 12 years
and older!
DUP.20.05.0112
  • a With DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood eosinophils ≥300 cells/μL (Trial 1, secondary endpoint).
  • b At Week 52 with DUPIXENT 300 mg + SOC (n=277) vs 230 mL improvement with placebo + SOC (n=142) in patients with baseline blood eosinophils ≥300 cells/μL (Trial 2, secondary endpoint).
  • c At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (Trial 3, primary endpoint).

EOS, eosinophils; OCS, oral corticosteroid.

References:

  1. Data on file, Sanofi US. IQVIA Patient Insights; data through March 2020.
  2. DUPIXENT Prescribing Information.
  3. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
  4. UnitedHealthcare. UnitedHealthcare Pharmacy Clinical Pharmacy Programs. 2019.